Recent activity in Washington—from the Patients Deserve Price Tags Act now moving through the Senate, to the House Ways and Means Committee hearing with Hospital CEOs in April—illustrates that dissatisfaction with the current state of healthcare delivery continues to grow. While pricing and affordability are the most visible part of…
In its latest annual report, IQVIA showed that the 340B drug pricing program has continued to grow at double digit rates. In 2025, 340B drug sales grew by 20.3% year-over-year reaching $179.5B. If you adjust this data for missing 340B sales, IQVIA projects that the 340B program is “approximately $200B,…
Sen. Bill Cassidy’s recently proposed discussion draft to reform the 340B Drug Pricing Program marks the most significant congressional effort in more than a decade to increase transparency, strengthen oversight and ensure the program better serves the vulnerable patients it was originally designed to help. Cassidy’s proposal deserves serious consideration.…
As I have covered in the first three columns of this series, the recent House Ways and Means Committee hearing exposed frustration with hospital pricing and affordability and highlighted that policymakers, employers and consumers are increasingly questioning the ability of the current healthcare business model to deliver value. Healthcare leaders…
The recent House Ways and Means Committee hearing reflected something larger than frustration with hospital pricing. It exposed a growing recognition that decades of effort trying to reform healthcare have produced mounting cost, rising dissatisfaction and little confidence that the current model can deliver results. Healthcare leaders should stop treating…
Biopharma new product strategic launch sequencing (SLS) is becoming increasingly more controversial and complex. In the first part of this article on biopharma new product SLS, we review the background and significant challenges the Biopharma industry faces in new product launch sequencing. In the second part, we discuss likely ramifications…
